Class / Patent application number | Description | Number of patent applications / Date published |
424215100 | Reoviridae (e.g., rotavirus, reovirus, orbivirus, avian proventriculitis virus, bluetongue virus, Colorado tick fever virus, etc.) | 35 |
20080292660 | Hexavalent Bovine Rotavirus Reassortant Composition Designed for Use in Developing Countries - The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided. | 11-27-2008 |
20090130145 | VACCINE - The invention provides an attenuated rotavirus population comprising a single variant or substantially a single variant which is defined by a nucleotide sequence encoding at least one of the major viral proteins designated as VP4 and VP7. The invention particularly provides a rotavirus population designated as P43. The invention further provides a novel formulation for a rotavirus vaccine which is in the form of a quick dissolving tablet for immediate dissolution when placed on the tongue. | 05-21-2009 |
20090136545 | PORCINE ROTAVIRUS REASSORTANT COMPOSITIONS - The present invention provides rotavirus reassortant immunogenic compositions based on a porcine rotavirus. In particular, porcine rotavirus Gottfried strain-based single VP7 or VP4 gene substitutions which can provide (i) an attenuation phenotype of a porcine rotavirus in humans and (ii) antigenic coverage for G serotypes 1, 2, 3, 4, 5, 6, 8, 9 and 10 and P serotype 1A[8], 1B[4] and 2A[6]. The compositions have been demonstrated to induce consistent levels of neutralizing antibodies against rotavirus specificities which are of global epidemiologic importance. Porcine rotavirus-based reassortant rotavirus compositions induce neutralizing antibodies against P1A[8] and P2A[6] VP4 serotypes which may provide an advantage over rhesus- or bovine-based reassortant vaccines since the VP4s of the latter vaccines do not evoke antibodies capable of neutralizing the P1A[8], or P2A[6] VP4. | 05-28-2009 |
20100047278 | Human Rotavirus and Vaccine Composition Comprising Same - Provided are G12 human rotaviruses having VP7 gene of SEQ ID NO: 1 or 2 and VP4 gene of SEQ ID NO: 3 or 4; antibodies specific for said rotaviruses; and a vaccine composition containing the same. The antibodies and the vaccine composition are effective for diagnosing rotavirus infection and for treatment of diseases caused by rotavirus. | 02-25-2010 |
20100047279 | IMMUNOLOGICAL COMPOSITION - The present invention relates to immunological compositions comprising sulpholipo-cyclodextrin (SL-CD) and, saponin or Quil A, and optionally at least one antigen. The invention relates to methods and immunological compositions comprising at least one antigen, which may be a veterinary antigen. The veterinary antigen in the methods and immunological compositions of the invention may be a bovine antigen. The invention relates to methods and immunological compositions comprising bovine ephemeral fever virus (BEFV), bovine herpesvirus 1 (IBR) or bluetongue virus (BTV). The invention comprises methods for eliciting an immune response against BEFV, IBR, or BTV in an animal, which comprises administering to the animal a composition of the invention. In the invention, particularly the immune response is a protective immune response. The invention comprises a method for preparing an immunological composition comprising adding Quil A to a virus. | 02-25-2010 |
20100055131 | REOVIRUS COMPOSITIONS AND METHODS OF USE - The present invention relates to novel strains of avian reovirus that were isolated from severe cases of Runting Stunting Syndrome in young broiler chickens in southeast United States. The invention is directed to avian reoviruses that impair digestion in poultry, diagnostic assays using nucleotide- or amino acid-specific components of such viruses, and to vaccines that protect chickens from disease caused by such viruses. Nucleotide sequences for the SI gene, encoding the sigma C minor outer capsid protein, were amplified, and the nucleotide and predicted amino acid sequences were compared with sequences from other recently isolated reovirus field isolates and vaccine strains. Antigenic and molecular characterization of the newly isolated reoviruses revealed a lack of homogeneity with current U.S. isolates, with less than 60% percent amino acid similarity across the sigma C protein. Sequence comparisons with previously reported malabsorption isolates from Europe and Asia revealed a higher amino acid similarity, approaching 80%. | 03-04-2010 |
20100068227 | Composition Useful as a Vaccine - The present invention relates to a composition comprising a viral antigen, a first protein and a second protein. Optionally, the composition also comprises three different disaccharaides, or, optionally, the composition comprises a primary sugar and at least one, preferably two secondary sugars. The present invention also relates to the use of a viral antigen, a first protein and a second protein for the manufacture of a composition, preferably a vaccine. The present invention furthermore relates to a method of treatment or prevention of virus associates diseases in humans. Moreover, the present invention relates to a method of adapting a virus to a suitable cell-line. The invention is also useful for the production of virus suspensions suitable for making stable, live/inactivated, monovalent and/or polyvalent, liquid/lyophilized rotavirus vaccine compositions for oral and/or nasal or any other suitable route of administration in human. | 03-18-2010 |
20100209455 | THERMAL INACTIVATION OF ROTAVIRUS - Methods of thermally inactivating a rotavirus are provided according to the present invention which include exposing the rotavirus to a temperature in the range of about 50° C.-80° C., inclusive, for an incubation time sufficient to render the rotavirus incapable of replication or infection. The thermally inactivated rotavirus is antigenic and retains a substantially intact rotavirus particle structure. Vaccine compositions and methods of vaccinating a subject against rotavirus are provided which include generation and use of thermally inactivated rotavirus. | 08-19-2010 |
20100226939 | FORMULATIONS FOR PRESERVATION OF ROTAVIRUS - This invention provides formulations and methods for stabilizing viruses in liquid and dried formulations. In particular, formulations are provided including Zn | 09-09-2010 |
20100233208 | Methods of Treating and Preventing Neurological Symptoms Caused by Avian Reovirus and Novel Associated Characteristics - Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms. | 09-16-2010 |
20100278863 | Reoviruses - The present invention provides a reverse genetics system for viruses belonging to the Reoviridae (i.e. Reoviruses), various uses thereof, genetically modified Reoviruses, Reovirus selection/production and propagation systems, medicaments and vaccines. | 11-04-2010 |
20100303859 | VECTORS AND METHOD FOR GENETIC IMMUNIZATION - Improved DNA vaccine plasmids are disclosed that contain novel immunostimulatory RNA compositions. The improved plasmids eliminate all extraneous sequences, incorporate a novel antibiotic free short RNA based selectable marker, increase eukaryotic expression using a novel chimeric promoter, improve yield and stability during bacterial production, and improve immunostimulation. These vectors are utilized in immunization to elicit improved immune responses or therapy to induce type 1 interferon production. | 12-02-2010 |
20100322971 | METHOD FOR PRODUCING VACCINAL VIRAL STRAIN OF A VIRUS OF THE REOVIRIDAE FAMILY - The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus. | 12-23-2010 |
20110027316 | BLUETONGUE VIRUS VACCINE AND IMMUNOGENIC COMPOSITIONS, METHODS OF USE AND METHODS OF PRODUCING SAME - Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection of ruminants with Bluetongue virus. Administration to an animal of at least one dose of an adjuvanted and twice inactivated Bluetongue virus composition as disclosed herein is effective in providing immunity to the animal and protection from infection with Bluetongue virus, thereby reducing the severity of and/or preventing disease caused by one or more strains or serotypes of Bluetongue virus. | 02-03-2011 |
20110091500 | Inactivated Live-Attenuated Bluetongue Virus Vaccine - The invention describes the preparation of an inactivated bluetongue virus (BTV) composition, and in particular a vaccine, using an attenuated live BTV vaccine strain as masterseed. The vaccine can be administered to an animal to prevent bluetongue disease by eliciting an immune response against the bluetongue virus serotype(s) included in the composition. | 04-21-2011 |
20110110980 | HETERLOGOUS PRIME-BOOST IMMUNIZATION REGIMEN - The invention provides methods of inducing an antigen-specific immune response in a subject by using a combination of immunogenic compositions. Generally, the method involves administering to the subject an effective amount of two different immunogenic compositions, both of which comprise bluetongue virus serotype 8. | 05-12-2011 |
20110150928 | UNIQUE AVIAN REOVIRIDAE - This invention relates to novel unique strains avian reoviridae that were isolated from severe cases of Runting Stunting Syndrome. The present invention also relates to the isolation and uses of novel unique avian reoviridae, diagnostic assays using nucleotide or amino acid specific components of such viruses, such as the sequence encoding Sigma C capsid protein and to vaccines that protect birds from diseases caused by such viruses. | 06-23-2011 |
20110236420 | BLUETONGUE VIRUS RECOMBINANT VACCINES AND USES THEREOF - The present invention encompasses BTV vaccines or compositions. The vaccine or composition may be a vaccine or composition containing BTV antigens. The invention also encompasses recombinant vectors encoding and expressing BTV antigens, epitopes or immunogens which can be used to protect animals, such as ovines, bovines, or caprines, against BTV. | 09-29-2011 |
20120107356 | COMPOSITION USEFUL AS ROTAVIRUS VACCINE AND A METHOD THEREFOR - Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children. | 05-03-2012 |
20120141528 | LYOPHILIZED VIRAL FORMULATIONS - Provided herein are lyophilized viral formulations useful for the stabilization and storage of viruses and methods of preparing these formulations. The lyophilized viral formulations described herein include a virus (e.g., a purified virus) and a non-viral composition including excipients. The formulations can be used, for example, to retain the infectivity or immunogenicity of viruses during periods of storage. | 06-07-2012 |
20120237547 | LIVE ATTENUATED ROTAVIRUS VACCINE FOR ORAL ADMINISTRATION - The invention provides liquid rotavirus formulations that are suitable for oral administration to human infants. In particular the invention provides pharmaceutical compositions and vaccines, comprising a rotavirus antigen, a sugar and a carboxylate wherein said formulation has a pH of between pH 5.0 and pH 8.0 and comprises no phosphate or less than 5 mM phosphate. The invention also provides methods of preparing said rotavirus formulations and use thereof in the prevention or treatment of rotavirus associated diseases in humans. | 09-20-2012 |
20130095135 | PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE PRODUCTION OF A VIRUS IN CELL CULTURE - The present invention relates to improved processes for the production of viruses, in particular, viruses for use in medicine (for example vaccination or gene therapy). | 04-18-2013 |
20130164329 | CELL-BASED METHODS AND REAGENTS - The present invention relates to compositions and methods for isolating cells devoid of unwanted viral contaminants, and to methods for preparing a virus stock substantially devoid of viral contaminants. Virus stocks, cells, and immunogenic reagents produced using such methods are also provided. | 06-27-2013 |
20130337010 | REASSORTANT BTV AND AHSV VACCINES - The present invention encompasses BTV and ASHV vaccines or compositions and methods of producing recombinant reassortant BTV and ASHV vectors and methods of vaccination against BTV and ASHV. | 12-19-2013 |
20140134209 | METHOD FOR PRODUCING VACCINAL VIRAL STRAIN OF A VIRUS OF THE REOVIRIDAE FAMILY - The invention relates to a method for producing a modified viral strain of a virus which is a member of the Reoviridae family and, in particular, relates to vaccinal viral strains of the Orbivirus genus. | 05-15-2014 |
20140242113 | LIQUID VACCINE PREPARATIONS - This document provides methods and materials involved in making and using liquid vaccine preparations for oral administration. For example, methods and materials for making and using liquid vaccine preparations for oral administration that include a lyophilized or dried vaccine component (e.g., a lyophilized pathogenic agent such as a lyophilized rotavirus preparation) and a liquid edible oil composition (e.g., a liquid edible oil composition containing one or more medium chain triglycerides) are provided. In some cases, liquid vaccine preparations that include a buffer component (e.g., CaCO | 08-28-2014 |
20140356396 | ROTAVIRUS PREPARATIONS WITH EXCESS CALCIUM IONS AND HIGH VISCOSITIES THAT ENSURE VIABILITY AT ELEVATED TEMPERATURES - The invention describes a set of formulations and methods that provide for stabilization of viruses in liquid and dried states. In particular, formulations include Rotavirus preparations with excess Ca2+ and high viscosities that ensure infective potency at elevated temperatures. Methods include bulk purification of Rotavirus from cell culture and administration of formulations as vaccines including components for gastric neutralization. | 12-04-2014 |
20140370054 | METHODS FOR INHIBITION OF TYPE 1 DIABETES - This disclosure is directed to methods of inhibiting the development of type 1 diabetes in a subject, including methods of preventing development of type 1 diabetes. The disclosed methods involve pre-partum vaccination of future mothers against rotavirus. Methods of decreasing the prevalence of type 1 diabetes are also disclosed. | 12-18-2014 |
20150098967 | ROTAVIRUS VACCINE COMPOSITIONS AND PROCESS FOR PREPARING THE SAME - Invention provides novel rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without requiring separate administration of an antacid before vaccine administration. Vaccine compositions with buffers of the invention are stable liquid rotavirus vaccine formulations for oral administration. | 04-09-2015 |
20150313991 | VACCINATION ADJUVANT, PREPARATION AND VACCINES CONTAINING THE SAME - The invention relates to the composition, preparation and use of a formulation as an adjuvant for human or animal use, said formulation comprising at least one bile acid or salts thereof and saponin, in order to enhance the immune response against an antigen, which may or may not be well defined, including but not limited to bacterins, antigens and antigenic preparations that are viral, bacterial or parasitic, and antigens associated with diseases such as different types of cancer. The antigens used can be isolated from pathogens, as well as products resulting from enzymatic or chemical modification, synthetic or recombinant antigens, or mixtures of the same. | 11-05-2015 |
20160058858 | BLUETONGUE VIRUS VACCINE AND IMMUNOGENIC COMPOSITIONS, METHODS OF USE AND METHODS OF PRODUCING SAME - Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating infection of ruminants with Bluetongue virus. Administration to an animal of at least one dose of an adjuvanted and twice inactivated Bluetongue virus composition as disclosed herein is effective in providing immunity to the animal and protection from infection with Bluetongue virus, thereby reducing the severity of and/or preventing disease caused by one or more strains or serotypes of Bluetongue virus. | 03-03-2016 |
20160082122 | NON-IMMUNOGENIC AND NUCLEASE RESISTANT NUCLEIC ACID ORIGAMI DEVICES AND COMPOSITIONS THEREOF - Nucleic acid origami devices are provided that are non-immunogenic and/or resistant to nucleases, which may be activated by one or more external cues, such as ligands, glucose concentration or electromagnetic fields; or used for attenuation or prevention of internalization of cell-surface receptors or prolongation of shelf-life of active agents. Further provided are methods for treating diabetes and methods for preparing the devices. | 03-24-2016 |
20160145583 | Methods for Preparing Inactivated Rotavirus - Disclosed are methods for production of inactivated rotavirus directly from cell culture supernatants containing active or infectious rotavirus (e.g., bovine rotavirus), without prior isolation or purification of the rotavirus from the cell culture supernatants In some embodiments, inactivated rotavirus (e.g., bovine rotavirus) is produced by heating a volume of culture supernatant to at least a temperature at which the rotavirus is inactivated. In some embodiments, the rotavirus (e.g., bovine rotavirus) is inactivated once the entire volume is heated to at least a temperature at which the rotavirus is inactivated. In some embodiments, the temperature of the cell culture supernatant is maintained for a suitable amount of time, which may be determined using any of the tests described herein. Inactivated rotavirus (e.g., bovine rotavirus) may then be isolated from the culture supernatant. | 05-26-2016 |
20160252300 | METHOD OF MICROWAVE VACUUM DRYING SPHERICAL-SHAPED PELLETS OF BIOLOGICAL MATERIALS | 09-01-2016 |
20190142932 | A Buffer Free, Acid Stable Low Dose Volume Rotavirus Vaccine | 05-16-2019 |